From The Stage

Cell and Gene Therapies Account for a Large Portion of the Therapeutics Market

Posted by BioAgilytix / / Gene Therapy, Industry Update

Cell and gene therapies have gone through a growth spurt in the last decade. According to data from the Alliance for Regenerative Medicine (ARM), during the first three quarters of 2020, regenerative medicine research and development broke records at nearly $16 billion in global financing. From the treatment of knee injuries to osteoarthritis, certain cancers and even muscular dystrophy, advances in gene and cell therapies have definitely caught the attention of medical professionals, and for good reason. Cell and Gene Therapies Account for a Large Portion of Therapeutic Market Share…

FDA RACE for Children Act: What You Should Know

Posted by BioAgilytix / / Industry Update

Short for Research to Accelerate Cures and Equity, the RACE Act went into effect on August 18, 2020, and significantly increased the number of required studies devoted to pediatric cancer research, drugs, and therapies. Originally enacted in August 2017, as a part of the Food and Drug Administration (FDA) Reauthorization Act (FDARA), the RACE Act is an amendment to the Federal Food, Drug, and Cosmetic Act (FFDCA) which was created to extend user-fee programs for drugs, medical devices, and biosimilars, as well as other biological products. Key Factors of the…

The Benefits of Hiring the Right CRO

Posted by BioAgilytix / / Industry Update

Short for Contract Research Organization, a CRO is a company that provides clinical research support to the pharmaceutical, biotech and medical industries on a contract basis. Contract Research Organizations are hired to offer research support and conduct clinical trials to safely and efficiently bring life-saving drugs and vaccines to market. Lasting partnerships between CROs and pharmaceutical companies are vital to the long-term success of ongoing programs and clinical trials. When a CRO fails to meet certain criteria relating to safety protocols or deadlines it can leave some companies questioning whether…

The Impact of Brexit on European Biotech and Biopharma

Posted by BioAgilytix / / Industry Update

At the commencement of her national campaign in July 2016, the former UK Prime Minister Theresa May stated, “It is hard to think of an industry of greater strategic importance to Britain than its pharmaceutical industry.” This still holds true today. Despite this, according to the Freedom of Information Act, as of 2017, the number of EU academics and staff departing the United Kingdom was up by over 35% compared to years prior. In fact, many companies, Biotech included, have been leaving the UK for the Netherlands only adding to…

What’s Happening at the 14th WRIB Virtual Meeting?

Posted by / / BioAgilytix Insight, Industry Update

We've compiled a guide to the presentations & forums our BioAgilytix team members will be participating in throughout the 2020 WRIB Virtual Meeting so you can join in the conversations too.

The Power of Being NYCE

Posted by / / Gene Therapy, Industry Update

A recent study using triple-edited ‘NYCE’ cells shows the possibilities of multiplex genome editing to effectively treat complex diseases like some cancers. We explore the promising results.

COVID-19: Testing for the “Cytokine Release Syndrome, CRS”

Posted by / / Biomarkers, Industry Update

New data suggests Cytokine Release Syndrome in patients with severe cases of COVID-19 may cause death. See how BioAgilytix can apply our validated MSD cytokine/chemokine panels to support cytokine monitoring in COVID-19 vaccine & therapeutic programs.

A Dose of Pharma and Biotech News: December 12, 2019

Posted by / / BioAgilytix Insight, Industry Update

With innovative research driving pharmaceutical and biotech breakthroughs, industry progress is accelerating at a rapid pace. We've compiled some recent industry articles on the latest topics to share with you.